Articles From: Deutsche Bank Held Back by Weak Eurozone, Strict Banking Laws - Executive to Epizyme DOT1L Inhibitor EPZ-5676 Shows Clinical and Biological Activity in Adult Patients with Acute Leukemias in Phase 1 Trial


2014/11/17
By Eyk Henning FRANKFURT--Europe's banks will lag behind U.S. rivals for the next several years because of the eurozone's weak economy and an unfavorable political environment, Deutsche Bank AG's (DB) co-chief executive Juergen Fitschen said Monday.
Sign-up for Deutsche Bank Held Back by Weak Eurozone, Strict Banking Laws - Executive investment picks
2014/12/11
CA Technologies (NASDAQ:CA) today announced it has been positioned by Gartner, Inc. in the Leaders quadrant of the “ Magic Quadrant for Integrated IT Portfolio Analysis Applications ”* for the third year in a row.
Sign-up for CA Technologies Positioned as “Leader” in Gartner Magic Quadrant Report for Integrated IT Portfolio Analysis Applications for Third Consecutive Year investment picks
Oplink Shareholders for Change (“OSC”), a group led by Engaged Capital, LLC (“Engaged Capital”) and Voce Capital Management LLC (“Voce Capital”), released today a letter to shareholders of Oplink Communications Inc. (“Oplink” or the “Company”) (NASDAQ:OPLK) highlighting the Board’s continued abandonment of their responsibility to call the Annual Meeting of shareholders.
Sign-up for Oplink Shareholders for Change (OSC) Release Letter to Fellow Shareholders investment picks
2014/9/17
TransMontaigne Partners L.P. (NYSE: “TLP”) announced today that its wholly-owned subsidiary, TransMontaigne Operating Company L.P., has entered into a long-term terminaling services agreement with Metroplex Energy, a wholly-owned subsidiary of RaceTrac Petroleum Inc. (“Metroplex”), relating to the receipt, storage and delivery of gasoline, ethanol and diesel fuel using tanks with an aggregate capacity of approximately 2.17 million barrels at its Cape Canaveral, Port Manatee, Port Everglades South and Tampa terminals.
Sign-up for TransMontaigne Partners L.P. Announces That It Has Entered into a Terminaling Services Agreement with Metroplex Energy Relating to Florida Refined Products Tankage investment picks
2014/11/18
By Fanny Liu TAIPEI--China Steel Corp.
Sign-up for China Steel Lowers Jan-Feb Local Prices by Average 1.71% investment picks
2014/11/28
By Fanny Liu TAIPEI--Taiwan predicts steady growth next year on strong demand in its semiconductor export markets, as falling oil prices keeps inflation in check and is likely to defer a rise in interest rates.
Sign-up for Taiwan Predicts Steady Growth Next Year investment picks
2014/11/24
By Fanny Liu TAIPEI--Taiwan's industrial output hit a new high in October, though the government warned that holiday-season stockpiling of iPhone and gadget components may have already peaked.
Sign-up for Taiwan Output Hits New High, but Government Warns of Slowdown investment picks
2014/12/2
By David Kudla Ford shares are poised for a Santa Claus rally of their own and a happy new year, as the company's investments in 2014 start to pay off going into 2015.
Sign-up for UPDATE: Santa's new sleigh is built Ford tough investment picks
2014/12/3
By Dominic Chopping STOCKHOLM--Pharmaceutical companies Meda AB (MEDA-A.SK) and Cipla Ltd.
Sign-up for Meda and Cipla Sue Apotex to Enforce Patents investment picks
By Yoree Koh and Devlin Barrett Twitter Inc. said Tuesday that it is suing the U.S. government for the right to disclose more detailed information on government surveillance of its users, furthering a clash between Silicon Valley and Washington, D.C., that has intensified in recent months.
Sign-up for Twitter sues U.S. government over user data requests investment picks
Deal expands presence of CYREN URL filtering technology throughout the region MCLEAN, Va.
Sign-up for CYREN Signs New Partner in Taiwan investment picks
2014/10/16
Registered investment advisors (RIAs) devote their careers to helping investors plan for their long-term financial needs, but only a small minority have taken time to map out the future expansion of their own firms.
Sign-up for TD Ameritrade Institutional Highlights Five Strategies to Help RIAs Drive – and Sustain – Transformational Growth investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0971620001&sourceType=1 http://www.ccnmatthews.com/logos/20051013-200.jpg TORONTO, ONTARIO --
Sign-up for Diamond Drilling to Begin Imminently at CBay's Devlin Property in Chibougamau investment picks
JACKSONVILLE, Fla.
Sign-up for CSX CFO Reiterates Expectations And Strategy For Long-Term Value Creation investment picks
2014/11/12
Balfour Beatty Construction recently celebrated the opening of its latest project in conjunction with Neal Richards Group on behalf of Forest Park Medical Center, a Texas-based physician-owned hospital system.
Sign-up for Balfour Beatty Celebrates Opening of $95.5 Million Fort Worth Hospital investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced, in conjunction with its development partner Eisai, that clinical data from the ongoing Phase 1 study of EPZ-6438 (E7438), an oral, small molecule inhibitor of EZH2, will be featured in a late-breaking oral presentation at the 26 th EORTC-AACR-NCI Symposium on Molecular Targets and Cancer Therapeutics, to be held November 18-21 in Barcelona, Spain.
Sign-up for Epizyme Announces Clinical Data from Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) to be Presented at EORTC-NCI-AACR Symposium investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a live audio webcast of its discussion of the Company’s clinical programs and pipeline at the ASH annual meeting on Monday, December 8, 2014, at 12:30 p.m. PT (3:30 p.m. ET). The webcast will be available in the Events and Presentations section under the Investor Relations section of the Company's website at www.epizyme.com , and an archived replay of the webcast will be available for 30 days after the presentation.
Sign-up for Epizyme to Webcast Company Presentation at American Society of Hematology (ASH) Annual Meeting on December 8, 2014 investment picks
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that Chief Medical Officer Eric Hedrick, M.D., has resigned from the Company, effective October 31, 2014.
Sign-up for Epizyme Announces Departure of Chief Medical Officer Eric Hedrick, M.D. investment picks
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that clinical and pre-clinical data on its first-in-class histone methyltransferase (HMT) inhibitors will be highlighted in oral and poster presentations at the 56 th annual meeting of the American Society of Hematology (ASH), to be held December 6-9 in San Francisco, Calif.
Sign-up for Epizyme Announces Clinical and Pre-Clinical Data to be Featured in Oral and Poster Presentations at American Society of Hematology (ASH) Annual Meeting investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in three upcoming events in October: About Epizyme, Inc. Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers.
Sign-up for Epizyme, Inc. to Present at Upcoming Events in October investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today presented pre-clinical data on EPZ-6438 (E7438), its oral, small molecule inhibitor of EZH2, in models of synovial sarcoma, a soft tissue sarcoma that typically affects young adults.
Sign-up for Epizyme Presents Pre-Clinical Data on EZH2 Inhibitor EPZ-6438 (E7438) in Models of Synovial Sarcoma investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the US Patent and Trademark Office has granted Notices of Allowance for US Patent Applications, Nos.
Sign-up for Epizyme Announces Notices of Allowance for US Patent Applications Covering PRMT5 Inhibitors and Methods of Cancer Treatment with PRMT5 Inhibitors investment picks
Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the publication on the website of the American Society of Hematology (ASH) of an abstract entitled “The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia”. The abstract contains preliminary data from the Phase 1 trial of EPZ-5676, a potent and selective inhibitor of the DOT1L histone methyltransferase (HMT). EPZ-5676 is being developed for the treatment of acute leukemia with alterations in the MLL gene (MLL-r) or partial tandem duplications within MLL (MLL-PTD). The Company plans to present updated data from the trial at the 56 th annual meeting of ASH in San Francisco, Calif.
Sign-up for Epizyme Reports Publication of Preliminary Findings from Phase 1 Study of DOT1L Inhibitor EPZ-5676 in ASH Annual Meeting Abstract investment picks
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced third quarter 2014 operating and financial results and confirmed 2014 guidance.
Sign-up for Epizyme Announces Third Quarter 2014 Financial Results and Provides Corporate Update investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a conference call and live audio webcast on Thursday, November 6, 2014, at 8:00 a.m. ET to report third quarter 2014 financial results and provide a corporate update.
Sign-up for Epizyme to Report Third Quarter 2014 Financial Results and Provide Corporate Update on November 6, 2014 investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Kenneth Bate, an independent consultant in the biotechnology industry, has been elected to the Company’s board of directors.
Sign-up for Epizyme Elects Kenneth Bate to Board of Directors investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced results from the Phase 1 dose escalation study of the investigational EZH2 inhibitor EPZ-6438 (referred to as E7438 by Eisai) administered orally as a single agent in patients with advanced solid tumors and B-cell non-Hodgkin lymphomas.
Sign-up for Phase 1 Dose Escalation Data for Epizyme EZH2 Inhibitor EPZ-6438 (E7438) Shows Single Agent Activity in B-Cell Non-Hodgkin Lymphomas and Malignant Rhabdoid Tumor investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the presentation of results from the company’s Phase 1 trial of EPZ-5676, a potent and selective inhibitor of the DOT1L histone methyltransferase (HMT). Epizyme, along with its partner Celgene, is developing EPZ-5676 for the treatment of acute leukemia with alterations in the MLL gene (MLL-r) or partial tandem duplications within MLL (MLL-PTD). The trial found that EPZ-5676 was generally safe and well tolerated across all dose cohorts and showed clinical and biological activity.
Sign-up for Epizyme DOT1L Inhibitor EPZ-5676 Shows Clinical and Biological Activity in Adult Patients with Acute Leukemias in Phase 1 Trial investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Deutsche Bank Held Back by Weak Eurozone, Strict Banking Laws - Executive to Epizyme DOT1L Inhibitor EPZ-5676 Shows Clinical and Biological Activity in Adult Patients with Acute Leukemias in Phase 1 Trial
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent